A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

Trial Profile

A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Frozen shoulder
  • Focus Therapeutic Use
  • Sponsors Auxilium Pharmaceuticals; Endo Pharmaceuticals
  • Most Recent Events

    • 26 Mar 2013 Top-line results published in a BioSpecifics Technologies Corporation media release.
    • 25 Mar 2013 Primary endpoint 'Range-of-motion (active forward flexion in the affected shoulder)' has been met.
    • 25 Mar 2013 Top-line results published in an Auxilium Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top